Antibodies
8 March 2007
MAT Biopharma Announced Today the Initiation of the Phase I/II Escalating Dose of Ferritarg P(R)28 February 2007
Cytogen Announces Initiation of Phase 1 Trial for Radiolabeled Antibody for the Treatment of Hormone-Refractory Prostate Cancer28 February 2007
Vaccinex Announces Antibody Development And Commercialization Alliance In Multiple Sclerosis And Oncology28 February 2007
EvoGenix and Vegenics announce collaboration27 February 2007
Positive recommendation for Avastin use in advanced or recurrent colorectal cancer in Japan24 February 2007
Avastin receives positive opinion in Europe for first-line treatment of women with metastatic breast cancer23 February 2007
New phase III study confirms positive outcome of Avastin in patients with advanced lung cancer15 February 2007
DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6(R) technology platform15 February 2007
Peregrine Pharmaceuticals Reports Positive Phase Ib Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C Infection14 February 2007
GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B(R) in systemic lupus erythematosus14 February 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs14 February 2007
Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement13 February 2007
BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials for Anticoagulant TB-4028 February 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia7 February 2007
ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B6 February 2007
AstraZeneca Licenses Regeneron’s Velocimmune(R) Technology For Discovering Human Monoclonal Antibodies6 February 2007
UCB Licenses BioWa’s POTELLIGENT(R) Technology for use in Antibody Research and Development3 February 2007
Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis26 January 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin’s LymphomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports